Immuno-oncology
Statistical issues and challenges in immuno-oncology
... While these guidelines have served us well in evaluat- ing chemotherapeutic agents, recent research experience in immuno-oncology has indicated that the clinical ben- efit from immunotherapy might extend ...
9
Immuno-oncology combinations: raising the tail of the survival curve.
... with immuno-oncology combinations, it will be important to establish a priori specific trial criteria for treatment discontinuation, which may incorporate standard or immune-related RECIST criteria, ...
23
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
... of oncology clinical trials in the new era of personalized medicine and immuno-oncology is that we owe it to our patients (and to ourselves as clinical/translational researchers) to be more efficient ...
10
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
... Challenges facing CIMACs in patient sample acquisition Ignacio Wistuba, MD (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA) discussed challenges faced by CIMACs concerning processing and handling ...
13
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement
... Methods: ASCO and the Society for Immunotherapy of Cancer (SITC) convened a working group that consisted of practicing medical oncologists, immunologists, clinical researchers, biostatisticians, and representatives from ...
10
The promise of Immuno-oncology: implications for defining the value of cancer treatment
... Immuno-oncology in the context of Cancer treatment Until recently, the basic arsenal for treating cancer included surgery, radiation therapy, chemotherapy, and more recently, targeted therapy, sometimes in ...
11
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
... The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted ...
16
Practical issues of biomarker-assisted targeted therapy in precision medicine and immuno-oncology era
... The concept of precision medicine is not new, as multiplex and very sensitive methods, or next-generation sequencing and matched targeted cancer therapies, have come to clinical practice. Substantial progress has been ...
5
Theranostics in immuno-oncology using nanobody derivatives
... of immuno-oncology and their promise as theranostics in the context of ...in immuno-oncology are vast, and translation of some of these methodologies in a clinical setting is either already ...
20
<p>Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma</p>
... Immuno-oncology (I-O) agents are an evolving treatment modality that harnesses the immune system to fi ght cancer. I-O has already been successfully used in the treatment of various tumour types with limited ...
12
<p>Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group</p>
... A standardized method for stromal TILs morphological evaluation was conducted according to the International Immuno-Oncology Biomarkers Working Group. The exclusion criteria were as follows: TILs outside of ...
13
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
... and immuno- stained for the presence of GrB with rabbit anti-GrB polyclonal antibody (Abcam, Cambridge MA), followed with Alexa Fluor 488-coupled donkey anti-rabbit ...
14
Immuno Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
... in oncology, summarizing the limitations of the 3 + 3 design of early phase clinical studies and outlining alternative designs that include immunotherapy ...
9
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes
... Medical Oncology (ESMO) has developed a reproducible tool which can be applied to new anticancer treatments to assess the mag- nitude of clinical benefit (ESMO Magnitude of Clinical Benefit ...
16
DLL3: an emerging target in small cell lung cancer
... with immuno- oncology therapies such as AMG 757 and AMG 119 are expected to provide us with a better understanding of the potential of this novel target and perhaps finally pro- vide patients with more ...
8
Approaches to modernize the combination drug development paradigm
... MTAs, immuno-oncology agents have produced impres- sive and durable tumor responses by reactivating host immunity and are approved for a growing number of in- dications, with combined ...
14
Ontogeny, pathology, oncology
... Int J De\' BioI 17 33 37 (1993) 33 Ontogeny, pathology, oncology VIRGINIA E PAPAIOANNOU' Department of Pathology, Tufts University Schools of Medicine and Veterinary Medicine, Boston, USA ABSTRACT Thi[.] ...
5
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
... Annals of oncology : official journal of the European Society for Medical Oncology / 376. ESMO[r] ...
22
Integrating psychosocial care into neuro-oncology: challenges and strategies
... in oncology settings, which include the continued dominance of biomedical care models; gaps in knowledge about research transla- tion; diminishing health budgets in the face of escalating costs; and individual and ...
6
Study On Psycho-Oncology Care In Medicine – Crucial Part of Oncology Treatment ( With Specific Research & Survey Conducted Among Oncology Patients)
... Pulassery, & Ravindran, 2004a). The social, moral, emotial and psychiatric care with medicine versus only the medical treatment without these factors can be well examined and understood with the trajectory curve. The ...
8